Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 51 to 60 of 281 total matches.
Antiviral Drugs for Influenza for 2023-2024
The Medical Letter on Drugs and Therapeutics • Nov 13, 2023 (Issue 1689)
or recombinant age-appropriate influenza vaccine.47
DRUG INTERACTIONS — Coadministration of
dairy products ...
Influenza is generally a self-limited illness, but
pneumonia, respiratory failure, and death can
occur, especially in patients at increased risk for
influenza complications (see Table 1). Antiviral drugs
recommended for treatment and chemoprophylaxis
of influenza for the 2023-2024 season are listed in
Table 2. Updated information on influenza activity
and antiviral resistance is available from the CDC at
www.cdc.gov/flu.
Med Lett Drugs Ther. 2023 Nov 13;65(1689):177-82 doi:10.58347/tml.2023.1689a | Show Introduction Hide Introduction
Two Drugs for Advanced HER2-Positive Breast Cancer (Enhertu and Tukysa)
The Medical Letter on Drugs and Therapeutics • Nov 16, 2020 (Issue 1611)
Two Drugs for Advanced HER2-Positive Breast Cancer (Enhertu and Tukysa) ...
The FDA has approved two new drugs for treatment
of previously-treated unresectable or metastatic
human epidermal growth factor receptor 2 (HER2)-positive breast cancer: fam-trastuzumab deruxtecannxki
(Enhertu – Daiichi-Sankyo/AstraZeneca), an IV
HER2-directed monoclonal antibody linked to the
topoisomerase I inhibitor DXd, and tucatinib (Tukysa – Seagen), an oral tyrosine kinase inhibitor.
Three Drugs for Atopic Dermatitis (Adbry, Cibinqo, and Rinvoq)
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023 (Issue 1673)
(Child-Pugh C).
DRUG INTERACTIONS — Use of live vaccines should
be avoided in patients who receive ...
The subcutaneously injected interleukin-13 (IL-13)
antagonist tralokinumab-ldrm (Adbry – Leo) and
the oral Janus kinase (JAK) inhibitors abrocitinib
(Cibinqo – Pfizer) and upadacitinib (Rinvoq – Abbvie)
have been approved by the FDA for treatment of
moderate to severe atopic dermatitis.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):51-5 doi:10.58347/tml.2023.1673b | Show Introduction Hide Introduction
Dolutegravir/Lamivudine (Dovato) - A Two-Drug Complete Regimen for HIV-1 Infection
The Medical Letter on Drugs and Therapeutics • Aug 26, 2019 (Issue 1579)
with
teratogenicity in humans and is generally considered
safe for use during pregnancy.6
DRUG INTERACTIONS — Drugs ...
The FDA has approved Dovato (ViiV), a fixed-dose
combination of the integrase strand transfer inhibitor
(INSTI) dolutegravir (Tivicay) and the nucleoside
reverse transcriptase inhibitor (NRTI) lamivudine
(Epivir, and generics), as a once-daily complete
regimen for treatment of adults with HIV-1 infection
who are antiretroviral-treatment naive and have no
known substitutions associated with resistance
to either drug. Dolutegravir/lamivudine is the first
complete regimen to be approved by the FDA for
initial treatment of HIV-1 infection that contains 2
rather than 3 antiretroviral...
Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only)
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only) ...
View the Table: Some Drugs for Inflammatory Bowel Disease
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e115-9 doi:10.58347/tml.2023.1680d | Show Introduction Hide Introduction
Comparison Table: Some Oral Anticoagulants for VTE (online only)
The Medical Letter on Drugs and Therapeutics • Jul 25, 2022 (Issue 1655)
Effects and
Drug Interactions Comments Cost2
Vitamin K Antagonist
Warfarin3 – generic
Jantoven (USL ...
View the Comparison Table: Some Oral Anticoagulants for VTE
Comparison Table: Some Parenteral Anticoagulants for VTE (online only)
The Medical Letter on Drugs and Therapeutics • Jul 25, 2022 (Issue 1655)
Adverse Effects and Drug
Interactions Comments Cost2
Unfractionated Heparin (UFH)
generic Prophylaxis ...
View the Comparison Table: Some Parenteral Anticoagulants for VTE
Table: Treatments Considered for COVID-19 (Archived) (online only)
The Medical Letter on Drugs and Therapeutics • Apr 06, 2020 (Issue 1595)
hyperbilirubinemia, rash, nephrolithiasis, cholelithiasis, PR interval prolongation
Drug Interactions:
Substrate ...
View the Table: Treatments Considered for COVID-19
In Brief: Dabrafenib (Tafinlar) and Trametinib (Mekinist) for Glioma (online only)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
aminotransferase levels have been
reported.
DRUG INTERACTIONS — Dabrafenib is an inducer
of UDP ...
The oral kinase inhibitors dabrafenib (Tafinlar –
GSK) and trametinib (Mekinist – Novartis) have been
approved by the FDA for use together for a sixth
indication: treatment of low-grade glioma (LGG)
with a BRAF V600E mutation in patients ≥1 years old
who require systemic therapy. This combination is
the first systemic therapy to be approved in the US
for first-line treatment of LGG with a BRAF V600E
mutation in pediatric patients. The FDA also approved
new oral formulations of both drugs for patients
who are unable to swallow dabrafenib capsules or
trametinib...
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e75-6 doi:10.58347/tml.2023.1674i | Show Introduction Hide Introduction
Rilonacept (Arcalyst) for Recurrent Pericarditis
The Medical Letter on Drugs and Therapeutics • Sep 06, 2021 (Issue 1632)
DRUG INTERACTIONS — Use of an IL-1 inhibitor with
a TNF inhibitor has been associated ...
Rilonacept (Arcalyst – Kiniksa), an interleukin-1 (IL-1)
antagonist that has been available for years for
treatment of cryopyrin-associated periodic syndromes,
has now been approved by the FDA for treatment
of recurrent pericarditis and prevention of further
recurrences in patients ≥12 years old. It is the first drug
to be approved in the US for this indication. Anakinra
(Kineret), an IL-1 receptor antagonist FDA-approved for
treatment of rheumatoid arthritis, has been used off-label
for years for treatment of recurrent pericarditis.